At the moment, the PD-1 and PD-L1 cancer immune-therapies need consistent treatment with anti-PD-L1/PD-1 antibodies that may be costly, alternatively CRISPR-Cas systems could be considered as an affordable and easy to use option [79]. This evidence concerns the gene CD274 and cancer.